PPARG and colitis: This study demonstrated that systematic administration of pioglitazone, an agonist of PPARγ, could alleviate DSS-induced colitis, attenuate colitis-associated mechanical hyperalgesia, and improve integrity of the intestinal mucosal barrier by directly upregulating tight junction proteins.